You are required to be logged in to access the full website
Click here if you have forgotten your username or password
Therapy Areas
28 October 2026 - Danish biotechnology company Genmab A/S (CPH:GMAB) on Wednesday announced positive topline results from its Phase 3 LiGeR-HN1 trial, showing that petosemtamab combined with pembrolizumab significantly improved overall survival and o...
28 October 2026 - Global oncology company Novocure (Nasdaq:NVCR) said on Wednesday that it has entered into a clinical trial collaboration and supply agreement with biopharmaceutical company Verastem Oncology (Nasdaq:VSTM) to evaluate Tumor Treating ...
28 October 2026 - US-based specialty pharmaceutical company US WorldMeds Ventures LLC announced on Tuesday a definitive merger agreement under which it has acquired Orbus Therapeutics Inc, a privately held pharmaceutical company developing investigat...
28 October 2026 - Japanese pharmaceutical company Astellas Pharma Inc (TSE:4503) and Australian biotechnology company Audax Biosciences Pty Ltd announced on Tuesday that they have entered into an exclusive option and licence agreement for DAX-044, Au...
28 October 2026 - Lynk Pharmaceuticals Co Ltd, a Chinese drug development company focused on immune and inflammatory diseases, on Tuesday announced positive long-term results from its pivotal Phase III clinical trial evaluating zemprocitinib, an inve...
27 October 2026 - Thor Medical ASA (OSE:TRMED), a supplier of alpha-emitters for precision cancer treatment, said on Tuesday that it has signed a three-year supply agreement with Medicines Discovery Catapult (MDC) to support the development of radiop...
27 October 2026 - Biopharmaceutical company AstraZeneca plc (LSE/STO/NYSE: AZN) and its Japanese pharmaceutical partner Daiichi Sankyo (TYO: 4568) said on Tuesday that the European Commission has approved Enhertu (trastuzumab deruxtecan) as a monothe...